Evotec
William Newsome has a diverse work experience spanning over two decades in the pharmaceutical and biotechnology industry. William currently serves as the President & CEO of Fibrocor Therapeutics, where their responsibilities include fundraising, program progression, and value creation. William also holds a position as a Non-Executive Board Director at Fibrocor. Prior to their current role, they held various positions at Evotec, including Senior Vice President, US Head of Strategic Alliance and Partnership Management, and Vice President of Strategic Business Development. William has also worked at DiscoveRx Corp as the Vice President of Corporate Development and Senior Director of Business Development. Earlier in their career, they served as the Director of Commercial Development at Molecular Devices and as a Biopharmaceutical Key Account Manager at Stratagene. William began their career as a Research Scientist at Pfizer Pharmaceuticals.
William Newsome earned an Associate of Arts degree from Berkshire Community College in 1988. William went on to obtain a Bachelor of Applied Science degree with a minor in chemistry from Colorado State University in 1992. Following this, they pursued a Master of Arts degree in Biochemistry and Molecular Biology at Brown University from 1996 to 2000.
This person is not in the org chart
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.